factually
Index/Organizations/Kisunla

Kisunla

Fact-Checks

3 results
Dec 5, 2025
Most Viewed

What are the costs, insurance coverage, and access issues for newly approved Alzheimer’s therapies in 2025?

New disease‑modifying monoclonal antibodies for early Alzheimer’s—lecanemab (Leqembi) and donanemab (Kisunla)—are expensive at scale (Leqembi cited at $26,500/year; Kisunla initial pricing described a...

Dec 18, 2025
Most Viewed

Is Neurocept FDA approved for Alzheimer's?

The documents provided show recent FDA approvals for anti-amyloid Alzheimer’s drugs — notably lecanemab (Leqembi) and donanemab (Kisunla/donanemab) — but contain no reporting that identifies or confir...

Jan 19, 2026

What treatments for Alzheimer are currently FDA-approved as of 2025?

As of 2025 the FDA’s approved arsenal for Alzheimer’s disease includes new anti-amyloid monoclonal antibodies for early-stage illness, longstanding symptom‑relief drugs, and a few recent approvals for...